Optimised genome editing in P. knowlesi enables transgenic expression of a lead P. vivax vaccine candidate, revealing roles in host cell tropisms and providing tools for scalable vaccine efficacy testing.

Biophysical and structural studies reveal how two inhibitory antibodies targeting CSP on malaria-causing Plasmodium vivax parasites lock its intrinsically flexible repeat into predominant coiled conformations, contributing molecular details of Pv inhibition by antibodies to enable structure-based engineering of PvCSP-based vaccines.

Host CD81 and Scavenger Receptor BI operate independently to mediate invasion of hepatocytes by different species of Plasmodium sporozoites, which use the parasite protein P36 as a key determinant of the entry route.

Mathematical models of the build-up and depletion of the hypnozoite reservoir in the liver can inform the design of treatment strategies for preventing Plasmodium vivax relapse infections.

Under sustained malaria control in PNG, the incidence of distinct blood-stage infections quantifies heterogeneity in transmission, significantly predicting risk of both P. falciparum and P. vivax malaria episodes at a population and individual scale.

Antibody responses to individual and optimal combinations of P. vivax recombinant proteins in naturally-exposed populations help to identify correlates of protective immunity, and establish a clear path to testing a multicomponent P. vivax vaccine.

Deforestation near villages is associated with short-term increases but long-term decreases in malaria incidence in Lao PDR, highlighting the influence of forest-going populations on malaria transmission in the region.

Data exploring host and parasite signatures in the peripheral blood indicate that total parasite biomass is a better predictor of P. vivax-induced host responses and pathogenesis than peripheral parasitemia.

Plasmodium parasites use host-derived factors to form more rosettes and hamper phagocytosis, representing a new escape mechanism for the malaria parasites.

The optimal allocation strategy prioritizes funding to high-transmission settings in sub-Saharan Africa, but highlights a trade-off between reducing clinical malaria burden and reducing the global population at risk of malaria.